SRP-5051 is an antisense oligonucleotide commercialized by Sarepta Therapeutics, with a leading Phase II program in Duchenne Muscular Dystrophy. According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of SRP-5051’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for SRP-5051 is expected to reach an annual total of $219 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
SRP-5051 Overview
Vesleteplirsen is under development for the treatment of Duchenne muscular dystrophy. It contains a PMO containing an exon 51 sequence (eteplirsen) with a cell-penetrating peptide. It is administered through intravenous route. The drug candidate is developed based on next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) technology and exon skipping technology which skips exon 51 in dystrophin gene and restores protein translation and dystrophin production.
Sarepta Therapeutics Overview
Sarepta Therapeutics (Sarepta) discovers and develops unique RNA-targeted medicines to treat rare diseases. The company develops its pipeline products using its multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing. The company’s platform is based on its pioneering work with phosphorodiamidate morpholino oligomer (PMO) chemistries. Its commercial products include Exondys 51, Vyondys 53, Elevidys and Amondys 45 indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene. Its pipeline product includes SRP-5051, SRP-9003 and SRP-9004 indicated for the treatment of DMD, limb-girdle muscular dystrophies (LGDMs) and other neuromuscular and central nervous system disorders. Sarepta is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$1,243.3 million for the fiscal year ended December 2023 (FY2023), an increase of 33.3% over FY2022. The operating loss of the company was US$583.5 million in FY2023, compared to an operating loss of US$664.2 million in FY2022. The net loss of the company was US$536 million in FY2023, compared to a net loss of US$703.5 million in FY2022.
The company reported revenues of US$362.9 million for the second quarter ended June 2024, a decrease of 12.2% over the previous quarter.
For a complete picture of SRP-5051’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
